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Edited by Angel NebredaAbstract Myocyte-speciﬁc enhancer factor 2A (MEF2A) regu-
lates a broad range of fundamental cellular processes including
cell division, diﬀerentiation and death. Here, we tested the
hypothesis that MEF2A is required in cardiac contractility
employing zebraﬁsh as a model organism. MEF2A is highly ex-
pressed in heart as well as somites during zebraﬁsh embryogen-
esis. Knock-down of MEF2A in zebraﬁsh impaires the cardiac
contractility and results in sarcomere assembly defects. Dysreg-
ulation of cardiac genes inMEF2A morphants suggests that sar-
comere assembly disturbances account for the cardiac contractile
deﬁciency. Our studies suggested that MEF2A is essential in
cardiac contractility.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Heart failure is a complex disorder in which cardiac contrac-
tility is insuﬃcient to adequately supply blood to other organs.
This syndrome is a common complication that ensues from a
wide variety of cardiovascular pathologies. Studies in failing
human hearts show numerous morphological changes includ-
ing degenerative alterations, mutation of contractile elements
and marked disorganization of sarcomere. These changes sug-
gest that defects of a contractile gene lead not only to de-
creased elastic properties of the sarcomere but also to
disturbances in sarcomerogenesis [1–4].
The zebraﬁsh, Danio rerio, oﬀers several distinct advantages
as a genetic and embryological model system, including the
external fertilization, rapid development and optical clarityAbbreviations: MEF2A, myocyte-speciﬁc enhancer factor 2A; hpf,
hours post fertilization; GFP, green ﬂuorescent protein; MO, mor-
pholino; vmhc, ventricular myosin heavy chain; amhc, atrial myosin
heavy chain; cmlc2, cardiac myosin light chain 2; anf, atrial natriuretic
factor; V, ventricle; A, atrium
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doi:10.1016/j.febslet.2005.07.068of its embryos. In addition, because of their small size, zebra-
ﬁsh embryos are not completely dependent on a functional car-
diovascular system. Even in the total absence of blood
circulation, they receive enough oxygen by passive diﬀusion
to survive and continue to develop in a relatively normal fash-
ion for several days, thereby allowing a detailed analysis of
animals with severe cardiovascular defects [5–11]. By contrast,
avian and mammalian embryos die rapidly in the absence of a
functional cardiovascular system. Forward genetics in zebra-
ﬁsh has led to the identiﬁcation of several mutations aﬀecting
cardiac contractility [10–13]. So far, in the large scale mutagen-
esis screens of zebraﬁsh, no mutations were linked to myocyte-
speciﬁc enhancer factor 2A (MEF2A) locus [8,10–14].
A loss-of-function mutation in the humanMEF2A causes an
autosomal dominant form of coronary artery disease [15,16].
These data have recently been put into question [17,18]. Dele-
tion of MEF2A in mice results in sudden cardiac death as well
as marked right ventricular dilation that is not explained by in-
creased pressure of the pulmonary vasculature [19]. Despite of
the sudden cardiac death phenotype, several diﬀerences exist
between these mice and humans with mutations in MEF2A.
More detailed phenotypic analysis of animals with MEF2A
mutations will be required to uncover its biological function.
In the present study, we described that MEF2A is highly ex-
pressed in the heart and somites during zebraﬁsh embryogen-
esis. And we provided the ﬁrst evidence that MEF2A is
required for zebraﬁsh cardiac contraction. MEF2A knock-
down results in sarcomere assembly defects, and the distur-
bances of sarcomere assembly could account for the cardiac
contractile deﬁciency.2. Materials and methods
2.1. Zebraﬁsh embryos
Wild-type (AB* strain) zebraﬁsh embryos were obtained from natu-
ral spawning of wild-type adults. Zebraﬁsh were raised, maintained
and staged as previously described [20,21].
2.2. RT-PCR analysis
Total RNA was extracted from diﬀerent stages embryos and adult
heart. RT-PCR was performed to amplify a 202 bp fragment, whose
authenticity was conﬁrmed by sequencing (MEF2A forward primer:
ATG CCC ACT GCC TAC AAC TC, reverse primer: CAT TCT
GGC TGG TGT TGA TG). Zebraﬁsh b-actin was used as control
for qualitative and quantitative assessment of the cDNA sampleation of European Biochemical Societies.
4844 Y.-X. Wang et al. / FEBS Letters 579 (2005) 4843–4850(b-actin forward primer: TAC AGC TTC ACC ACC ACA GC,
reverse primer: AAG GAA GGC TGG AAG AGA GC).The size of
the b-actin amplicon is 206 bp.2.3. Morpholino modiﬁed antisense oligonucleotide and microinjections
We designed one morpholino modiﬁed antisense oligonucleotide
(MO, Gene Tools, LLC) against the splice donor site of MEF2A exon
8 to interfere with splicing (GT-MO) and another MO directed against
the 5 0 sequence around the putative start codon to block MEF2A
translation (ATG-MO). The sequences for the GT-MO and ATG-
MO were the 5 0-GTCGTTTGTGCTCACCAGAGTTGTA-3 0 and
5 0-ATCTGTATCTTCTTCCGTCCCATCT-3 0, respectively. A stan-
dard control MO was designed for control microinjections. The
sequence for the standard control MO was 5 0-CCTCTTACCT-
CAGTTACAATTTATA-30. Wild-type embryos were injected at the
one-to-two cell stage with 2.5–10 ng MO per embryo.2.4. Microinjection of the MEF2A promoter construct in zebraﬁsh
embryos
TheMEF2A-green ﬂuorescent protein (GFP) construct was made by
linking the 1.7-kb MEF2A promoter with the GFP reporter gene. The
construct was linearized and dissolved in 5 mM Tris–HCl, pH 8.0,
200 mM KCl, 0.05% phenol red to a ﬁnal concentration of 50 ng/ml.
About 3 nl of the DNA sample was microinjected into the cytoplasm
of the one-to-two cell stage embryos. By using a ﬂuorescence micro-
scope, we observed the green ﬂuorescence in embryos.2.5. In situ hybridization, immunoﬂuorescence and photography
In situ hybridization experiments with Titin antisense were per-
formed as previously described [22]. Whole mount immunoﬂuores-
cence experiments were performed as previously described [22], using
the monoclonal antibodies MF20 and CH1, which recognizes a sarco-Fig. 1. MEF2A is highly expressed in the heart and somites during zebraﬁsh e
isolated from diﬀerent stages embryos and adult heart. MEF2A speciﬁc pro
embryos and adult heart. The b-actin primers ampliﬁed a single fragment in a
observed inMEF2A-promoter–GFP transgenic embryos. (B,C) Lateral views
muscle cells. (D,E) Lateral views at 48 the hpf, anterior to the left. GFP expre
bright ﬁeld.) Scale bar, 100 lm.meric myosin heavy chain epitope and a tropomyosin epitope. MF20
and CH1 developed by Dr. Donald A. Fischman and Dr. Jim Jung-
Ching Lin were obtained from the Developmental Studies Hybridoma
Bank developed under the auspices of the NICHD and maintained by
the University of Iowa, Department of the Biological Sciences, Iowa
City IA 52242. Stained embryos were examined with Olympus BX61
and SZX12 microscopes, and photographed with a DP70 digital cam-
era. Images were processed using Adobe Photoshop software.2.6. Western blot
Western blot were performed as previously described [21]. The
blots were incubated with the primary antibody diluted in TBST
(1:200 dilution for rabbit polyclonal anti-human MEF2A antibody
(C-21;Santa Cruz) and 1:500 dilution for mouse monoclonal b-ac-
tin antibody (AC-40; Sigma)). After incubating with an anti-rabbit
or anti-mouse IgG-horseradish peroxidase-conjugated secondary
antibody (diluted 1:1000) at room temperature for 1 h, the blots
were visualized by ECL kit according to the manufacturers
instructions.
2.7. Heart rates measurement and ventricular contractility analysis
Embryos were anesthetized and transferred to a recording chamber
perfused with modiﬁed Tyrodes solution (136 mM NaCl, 5.4 mM
KCl, 0.3 mM NaH2PO4, 1.8 mM CaCl2, 1 mM MgCl2, 10 mM
HEPES, 5 mM glucose, pH 7.3) at 48 h post fertilization (hpf). Heart
rates were accounted under a dissect microscope. Cardiac contractions
were recorded with a video camera (JVC, TK-C1381) as described [23].
The lengths of ventricles in diastolic and systolic conditions were mea-
sured to calculate the ventricular shortening fraction (VSF). Values are
presented as mean ± S.D.VSF ¼ ventricular length at diastole ventricular length at systole
ventricular length at diastole
.mbryogenesis. (A) RT-PCR analysis was performed with RNA samples
ducts were ampliﬁed from RNA isolated from 24 hpf, 48 hpf whole
ll the samples. (B–E) Transient expression patterns of GFP ﬂuorescence
at the 24 hpf, anterior to the left. GFP expression is observed in skeletal
ssion is observed in both heart and somites. (B,D: ﬂuorescent ﬁeld. C,E:
Y.-X. Wang et al. / FEBS Letters 579 (2005) 4843–4850 48452.8. Transmission electron microscopy
Embryos were ﬁxed at 48 hpf with 2% paraformaldehyde and 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buﬀer, postﬁxed with 1%
osmium tetraoxide followed by 1% uranyl acetate, dehydrated through
a graded series of ethanol washes, and embedded in LX112 resin.
Ultrathin (80 nm) sections were cut on a Reichert Ultracut UCT,
stained with uranyl acetate followed by lead citrate, and viewed on a
JEOL 1200EX transmission electron microscope at 80 kV.Fig. 2. Target sites of theMEF2AMOs and aberrant splicing ofMEF2A tra
indicate the two antisense oligos, GT-MO and ATG-MO, and the PCR prim
TCA AGG TTC AAT GCA CAG AAG CGT AGT G. Reverse primer (PCR
MO hybridizes to the start codon and is expected to block translation. GT-M
exon deletion caused by the GT-MO is conﬁrmed by RT-PCR of total RNAs
1–3: lane 1, 2.5 ng; lane 2, 5 ng; lane 3, 10 ng) or Con-MO (lanes 4–6: lane 4, 2
deletion product is seen in the GT-MO injected ﬁsh only, whereas the 541 bp
samples) and 9 (pool of Con-MO samples) are no RT controls. Lane 7 is DN
on (A). (C) The amount of wild-typeMEF2A mRNA in GT-MO injected an
RT-PCR analysis. The amount of MO injected per embryo is indicated. PCR
PCR): CCC CCA TCC AGC AA. Reverse primer (RQ-PCR): GCT TAT CC
injection. Western analysis of 24 hpf-embryos injected with MEF2A or cont2.9. RNA isolation and quantitative real-time PCR analysis
Total RNA was extracted from twenty microdissected hearts of 48
hpf embryos or ten 24 hpf embryos using the TRIZOL method and re-
verse transcribed using oligo-dT primer following the manufacturers
instructions. For all experiments, cDNA was quantiﬁed using Applied
Biosystems Sequence Detection System 7300. The SYBR green method
was used to quantify cDNA. The sequence-speciﬁc primers (primers se-
quences available on request) were designed using Primer Express2.0nscript. (A) Genomic organization of zebraﬁshMEF2A. Arrowed lines
ers used to detect targeted exon skipping. Forward primer (PCR-F):
-R): GAT GGA GAG GTT TGA GCC CTG AGG TAA GT. ATG-
O targets the splicing of the exon labeled ‘‘targeted exon’’. (B) Targeted
isolated from 10 individual embryos injected with either GT-MO (lanes
.5 ng; lane 5, 5 ng; lane 6, 10 ng). A 414 bp band representing the exon 8
wild-type band is detected in both groups. Lanes 8 (pool of GT-MO
A ladder (bp = base pairs). PCR strategy is summarized in the diagram
d Con-MO injected embryos were determined by quantitative real-time
strategy is summarized in the diagram on (A). Forward primer (FQ-
T CTG GGT GTT C. (D) Knock-down of MEF2A protein by MO
rol MOs at the indicated doses.
Fig. 3. Knock-down ofMEF2A leads to cardiac contractility defects. (A–G) Lateral views with anterior to the left. (A,B) The overall morphology of
a MEF2A GT-MO-injected (A,C) and Con-MO-injected (B,D) embryos at 28 hpf (A,B) and 48 hpf (C,D). (A 0,B 0) Lateral views of titin expression,
which marks each somite border in GT-MO-injected (A 0) and Con-MO-injected (B 0) embryos at 28 hpf. (E-G) Whole-mount immunoﬂuorescence
with the anti-tropomyosin antibody CH1 (FITC) to show the cardiac morphology inMEF2A knock-down embryos. Ventricle (V) and atrium (A) are
indicated. At 48 hpf, 11% (n = 45) of theMEF2A knock-down embryos show dilation of the atria and/or ventricles (E) compared with the control (G)
embryos. 89% (n = 45) of the MEF2A morphants ventricles and atria are normal without obvious structural defects (F). (H,I) Comparison of the
heart rate (H) and ventricular shortening fraction (I) inMEF2A knock-down and control embryos at 48 hpf. Scale bars: A–D, 100 lm; E–G, 50 lm.
Table 1
Phenotypes of wild-type embryos injected with MEF2A MOs
Morpholino n Phenotype
Normal Downward tail
curvature
Cardiac contractility
defects
Downward tail curvature
and cardiac contractility defects
GT-MO (10 ng) 49 1 (2%) 45 (92%) 29 (59%) 25 (51%)
ATG-MO (15 ng) 50 2 (4%) 44 (88%) 26 (52%) 23 (46%)
Con-MO (15 ng) 50 48 (96%) 1 (2%) 2 (4%) 0 (0%)
Downward tail curvature phenotype was assayed by the shape at 28 hpf. Cardiac contractility was assayed by measuring the ventricular shortening
fraction at 48 hpf.
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Y.-X. Wang et al. / FEBS Letters 579 (2005) 4843–4850 4847software (Applied Biosystems, USA). No-RT controls and water con-
trols gave similar high threshold cycle values, demonstrating that con-
tamination contributed to less than 0.1% of quantiﬁed product. The
input cDNA was normalized for PCR by using primers speciﬁc for
b-actin. Data were expressed as level of expression relative to standard
control-injected embryos set at 1 ± S.D. (n = 3).
2.10. Online supplemental material
Supplemental video material is available online. The videos show the
heart beat of a MEF2A knock-down embryo (Movie 1) and a control
embryo (Movie 2) at 48 hpf.3. Results
3.1. MEF2A is highly expressed in zebraﬁsh heart and somites
during zebraﬁsh embryogenesis
RT-PCR time course analysis of the zebraﬁsh MEF2A
expression pattern was performed with cDNA from 8, 24, 48
hpf-stage embryos and adult heart. MEF2A expression was
detectable at 24 hpf, 48 hpf and adult heart (Fig. 1A, [24]).
To better understand MEF2A tissue-speciﬁc expression during
zebraﬁsh embryogenesis, we isolated 5 0 ﬂanking sequences of
the zebraﬁshMEF2A gene and used a GFP transgenic strategy
to generateMEF2A-GFP transgenic zebraﬁsh. GFP expression
was observed in skeletal muscle cells at 24 hpf (Fig. 1B and C).
At 48 hpf, GFP expression was observed in both heart and
somites (Fig. 1D and E). The GFP expression pattern suggests
thatMEF2A expression is largely speciﬁc to cells of the somitic
and cardiac lineages.
3.2. Eﬀective targeted knock-down MEF2A in zebraﬁsh
To determine the function of MEF2A in zebraﬁsh devel-
opment, we performed gene knock-down experiments using
two diﬀerent MO antisense oligonucleotides (GT-MO and
ATG-MO) targeting the zebraﬁsh MEF2A [25,26]. We de-
signed the GT-MO directed against the donor site of exon
8 in MEF2A. Blocking the donor site of an exon can cause
skipping of the targeted exon and/or retention of the intron
[27,28]. We traced eﬃciency of the MEF2A GT-MO by RT-
PCR with primers ﬂanking the targeted exon on GT-MO-in-
jected and standard control morpholino (Con-MO)-injected
embryos at diﬀerent time-points. RT-PCR on RNA from
GT-MO-injected embryos at 28 hpf produced PCR products
that lacked exon 8 (Fig. 2A and B). As late as 6 days postFig. 4. Sarcomeric structures are disrupted inMEF2A morphants hearts. Tra
Myoﬁbrils (MF) are evident in the cardiomyocytes of both control (A) and M
embryonicl cardiomyocytes fromMEF2A morphants were the myoﬁbrillar dfertilization, the GT-MO modulated mRNAs were still
detectable (data not shown). Sequencing of the PCR product
lacking exon 8 showed that the loss of exon 8 resulted in a
frameshift in the MEF2A mRNA and hence premature
translation termination. The truncated protein would con-
tain 3 missense amino acids and would terminate after ami-
no acid 269. We next quantiﬁed the ability of GT-MO to
reduce the amount of correctly spliced MEF2A mRNA by
quantitative real-time RT-PCR analysis. We injected GT-
MO into embryos at doses ranging from 2.5 to 10 ng MO/
embryo and harvested RNA at 24 hpf. Using a SYBR green
real-time RT-PCR analysis, we found that injection of GT-
MO reduced the amount of wild-type MEF2A mRNA in a
dose-dependent manner (Fig. 2C). Because injection of
10 ng GT-MO per embryo reduced the amount of wild-type
message to levels that were undetectable in our assay
(Fig. 2C and D), we chose this amount for all subsequent
experiments involving GT-MO induced knock-down of
MEF2A. To demonstrate that only the truncated MEF2A
protein is present in 10 ng GT-MO-injected embryos, we
performed western blot assay using a speciﬁc anti-human
MEF2A antibody (C-21). The MEF2A antibody was raised
against a peptide mapping at the carboxy terminus of
MEF2A of human origin [15]. As shown in Fig. 2D, a dra-
matic decrease in the levels of MEF2A protein was observed
after the injection of 5 ng of the GT-MO, and complete loss
of detectable MEF2A protein was observed after injection of
10 ng/embryo of the same MO.
A second MO (ATG-MO) was designed against the start
codon to block translation of the MEF2A mRNA
(Fig. 2A and D) [25]. To determine the phenotype after
‘‘knock-down’’ of the MEF2A protein, we determined the
minimum amount of the ATG-MO that could eﬀectively
block MEF2A protein synthesis in vivo. As shown in
Fig. 2D, a dramatic decrease in the levels of MEF2A pro-
tein was observed after the injection of 7.5 ng of the
ATG-MO, and complete loss of detectable MEF2A protein
was observed after injection of 15 ng/embryo of the same
MO. By contrast, the injection of 15 ng of the Con-MO
had no eﬀect on the levels of MEF2A. Thus, we injected
MOs at the dosage of 15 ng/embryo to investigate the
embryonic phenotype resulting from a knock-down of the
MEF2A protein.nsmission electron microscopy of zebraﬁsh embryonic hearts at 48 hpf.
EF2A knock-down (B) embryos. The most salient diﬀerences between
isorganization in the cardiac muscle. MF, myoﬁbril. Scale bar, 300 nm.
4848 Y.-X. Wang et al. / FEBS Letters 579 (2005) 4843–48503.3. Knock-down of MEF2A leads to cardiac contractility
defects
We analyzed the phenotype in animals injected with either
MEF2A GT-MO or ATG-MO. Phenotypes of wild-type em-
bryos injected with MEF2A MOs were summarized in Table
1. In the early stages, MEF2A knock-down embryos display a
downward tail curvature (Fig. 3A–D). Titin expression marks
the segment borders of wild-type embryos [29]. The irregular
posterior somite borders in MEF2A knock-down embryos
(Fig. 3, compare A 0 with B 0) implicates that MEF2A is impor-
tant in zebraﬁsh somite development. Injection of the GT-MO
or the ATG-MO caused cardiac contractility defects that are
obvious in live embryos at 48 hpf (see Supplement Movie 1).
A obvious characteristic blood pool caudal to theMEF2Amor-
phants atria indicates that blood ﬂow is ineﬃcient (see Supple-
ment Movie 1). In control embryo, the ventricle and atrium
exhibit vigorous, rhythmic contractions (see supplement Movie
2). At 48 hpf, 11% (n = 45) of theMEF2AGT-MO-injected em-
bryos show noticeable dilation of the atria and/or ventricles
(Fig. 3E) compared with the Con-MO-injected embryos
(Fig. 3G). The normal cardiac morphology was visible in 89%
(n = 45) of the GT-MO-injected embryos (Fig. 3F). In control
embryos, the ventricles and atria exhibit vigorous, rhythmic
contractions, ensuring circulation throughout the body. At 48
hpf, control ventricles and atria contracted at 150 ± 6 beats
per minute (n = 20), whileMEF2Amorphants ventricles and at-
ria contracted at 107 ± 13 beats per minute (n = 20; P < 0.01;
Fig. 3H). We quantiﬁed cardiac contractility by measuring the
ventricular shortening fraction (VSF) [23,30]. The average
VSF of the wild-type siblings is 21 ± 2% (n = 10), whereas the
VSF value drops to 9.7 ± 0.9% in MEF2A morphants hearts
(n = 10; P < 0.01; Fig. 3I), demonstrating that MEF2A pos-
sesses an important role in regulating cardiac contractility.3.4. MEF2A is involved in assembly of the cardiac contractile
apparatus
The functional defects in MEF2A morphants suggest that
the cardiac contractile apparatus is abnormal. We compared
sarcomere assembly in control embryos and MEF2A knock-
down embryos at 48 hpf. At this stage, the control heart
exhibits nascent sarcomeres containing both thick and thin
ﬁlaments, and the nascent myoﬁbrils assemble into higher-
order sarcomere structures (Fig. 4A) [31]. By contrast, the most
salient diﬀerences between embryonic cardiomyocytes from
MEF2A knock-down embryos were the myoﬁbrillar disorgani-
zation (Fig. 4B). These data suggest that MEF2A inhibition
causes sarcomere assembly defects. The failure to generate nor-
mal sarcomeres most probably underlies the inability of the
MEF2A morphant heart to generate signiﬁcant systolic force.3.5. Dysregulation of cardiac genes in MEF2A morphants hearts
To further investigate the molecular basis for the cardiac
abnormalities in MEF2A morphants, we performed real-time
PCR analysis of the gene expression proﬁles of hearts from
MEF2A knock-down embryos and control embryos at 48
hpf. From this analysis, we detected alterations in expression
of cardiac contractile apparatus genes and key transcriptional
factors genes. In particular, troponon C, troponon T, atrial
myosin heavy chain (amhc), cardiac myosin light chain 2 (cmlc2),
a-tropmyosin and tbx5 were downregulated in MEF2A mor-
phants hearts 0.38 ± 0.04-fold, 0.45 ± 0.02-fold, 0.18 ± 0.01-fold, 0.13 ± 0.08-fold, 0.45 ± 0.16-fold and 0.09 ± 0.10-fold,
respectively. a-Actin and ventricular myosin heavy chain (vmhc)
were only weakly downregulated 0.70 ± 0.12-fold and
0.67 ± 0.17-fold, respectively. In contrast, MEF2D and
nkx2.5 were upregulated 1.98 ± 0.34-fold, and 3.29 ± 0.56-
fold, respectively (Fig. 5A). MEF2D was upregulated in
MEF2A morphant heart, suggesting that perhaps it was com-
pensating for the lack of MEF2A at this stage. Based on the
results from real-time PCR analysis, which suggested that a
gene program characteristic of cardiac contractility and heart
failure had been dysregulated in MEF2A morphants hearts,
we used whole mount immunoﬂuorescence to examine the
expression of genes known to be involved in cardiac contractil-
ity [1]. In agreement with the real-time PCR results, whole
mount immunoﬂuorescence showed that expression of mhc
(Fig. 5B and C) and a-tropmyosin (Fig. 5D and E) was down-
regulated in MEF2A morphants hearts at 48 hpf. Together,
MEF2A expression pattern, knock-down experiment, cardio-
myocytes electron microscopy observation and the dysregula-
tion of cardiac genes indicate that MEF2A is required in
zebraﬁsh cardiac contractility.4. Discussion
Comparing protein sequences, zebraﬁsh MEF2A is 72.7%
identical to human MEF2A, and 63.2% identical to that
of mouse, indicating that MEF2A structure is highly con-
served. MEF2 was ﬁrst described as a muscle-enriched tran-
scription factor that bound to an A/T-rich DNA sequence in
the control regions of numerous muscle-speciﬁc genes.
MEF2 proteins are nearly identical at their N-termini; where
they have a MADS domain (present in MCM1, Agamous,
Deﬁciens and Serum response factor). This domain mediates
dimerization and binding to the DNA sequence CTA(A/
T)4TAG/A [32]. An adjacent MEF2-speciﬁc domain inﬂu-
ences DNA-binding aﬃnity and cofactor interactions, and
the C-terminal regions of MEF2 proteins are required for
transcriptional activation [15,16,32]. The splice donor site
MO directed against zebraﬁsh MEF2A exon 8 can cause
skipping of the targeted exon. The loss of exon 8 caused a
frameshift in the MEF2A mRNA. This mutation that we
identiﬁed is predicted to lead to a complete loss of function,
as it deletes most of the DNA-binding homeodomain and
the entire C-terminal portion of MEF2A.
This report has identiﬁed a novel function ofMEF2A involved
in cardiac contractility employing zebraﬁsh as a model. In sum-
mary, a knock-down ofMEF2A function in zebraﬁsh impaired
the cardiac contraction. MEF2A knock-down results in sarco-
mere assembly defects, and disturbances of the sarcomere
assembly may account for the cardiac contractile deﬁciency.
The MEF2A-promoter–GFP transgenic zebraﬁsh analysis
and whole mount in situ hybridization experiments strongly
support that MEF2A gene expression marks the cardiac and
skeletal muscle lineages during zebraﬁsh embryogenesis. The
expression of MEF2A continues in adult heart. These expres-
sion patterns show that MEF2A is a key transcriptional factor
involved in cardiomyocyte function and dysfunction.
The phenotypes of MEF2A morphants reveal essential
roles for MEF2A in maintenance of cyto-architectural integ-
rity in post-natal cardiac myocytes. Several genes involved in
Fig. 5. Changes in gene expression in MEF2A morphants hearts. (A) Altered gene expression in hearts from MEF2A knock-down embryos
compared with control embryos. (B–E) Whole-mount immunoﬂuorescence with the monoclonal antibody MF20 (TRITC), which recognizes a
sarcomeric myosin heavy chain epitope found in both the ventricle and atrium, and the anti-tropomyosin antibody CH1 (FITC) to show the
downregulation of mhc and a-tropmyosin. Lateral views with anterior to the left. (B,C) Comparison ofMEF2A knock-down (B) and control embryos
(C) indicates downregulation of mhc expression throughout the MEF2A knock-down heart at 48 hpf. (D,E) Likewise, the MEF2A morphant heart
exhibits downregulation of a-tropmyosin expression at this stage. Ventricle (V) and atrium (A) are indicated. Scale bar, 50 lm.
Y.-X. Wang et al. / FEBS Letters 579 (2005) 4843–4850 4849zebraﬁsh myogenesis have promoters or enhancers that bind
MEF2A (Y. Wang, T.P. Zhong and H. Song, unpublished
data). Some of these genes have essential roles in sarcomer-
ogenesis. These data may explain the cardiac contraction de-
fects that we observed in the MEF2A knock-down zebraﬁsh
embryos. Studies in heart development and diseases show
mutations of contractile elements give the same kind of sar-
comere defects phenotypes [1–4]. The sarcomere assembly
defects in MEF2A morphants hearts could be an indirect ef-
fect of MEF2A. It is likely that MEF2A couples with other
transcription factors to regulate cardiac diﬀerentiation.MEF2D was upregulated in MEF2A morphants hearts, sug-
gesting that perhaps it was compensating for the lack of
MEF2A at this stage. It has been reported that MEF2D can
be activated by stress-responsive signaling pathways
[19].MEF2A morphants hearts might evoke a stress response.
Currently, there are four known members of the MEF2 family
termed MEF2A, MEF2B, MEF2C, and MEF2D. The speciﬁc
MEF2 isoform is expressed in distinct patterns and has distinct
function during embryogenesis. Although MEF2D was upreg-
ulated in MEF2A morphants hearts, it cannot compensate
MEF2A deﬁciency completely.
4850 Y.-X. Wang et al. / FEBS Letters 579 (2005) 4843–4850Our results open avenues for understanding the molecular
mechanism of heart development and diseases. Investigating
the multilevel controls that regulate contractile protein expres-
sion represents fascinating problems for the future.
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